Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Long-Acting Overactive Bladder Drugs Have Less Risk – Consumer Reports

  • News

Executive Summary

Extended-release forms of overactive bladder drugs have better side effect profiles than their shorter-acting counterparts, according to Consumer Reports September 2006 "Best Buy Drugs.

You may also be interested in...



Older Antipsychotic Tops New Branded Drugs In Consumer Reports Review

Generic perphenazine is recommended as first-line treatment for schizophrenia by Consumer Reports Best Buy Drugs based on a comparison of efficacy, adverse events and cost-effectiveness of 13 antipsychotic drugs

Older Antipsychotic Tops New Branded Drugs In Consumer Reports Review

Generic perphenazine is recommended as first-line treatment for schizophrenia by Consumer Reports Best Buy Drugs based on a comparison of efficacy, adverse events and cost-effectiveness of 13 antipsychotic drugs

Benzodiazepines, OTCs Are As Effective As Newer Rx Sleep Agents - Article

Newer insomnia treatments are no more effective than benzodiazepines and OTC antihistamines, Consumer Reports' August 2006 "Best Buy Drugs" report says

Table

View full table

Tags:
Latest Headlines

Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development

EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications

Industry & Regulators To Align Advice on COVID-19 Vaccine Updates

Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines

See All
UsernamePublicRestriction

Register

PS047576

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By